Introduction: Hepatocellular carcinoma (HCC) is the leading primary liver malignancy and is a major reason of cancer related death worldwide. Sorafenib is considered as the approved drug of choice in advanced HCC, which is an oral multikinase inhibitor with effective anti-proliferative and antiangiogenic effects. Currently, only limited data is available in India regarding the safety and effectiveness of Sorafenib for the management of HCC. Objectives: To evaluate the clinical profile of Sorafenib for treating advanced HCC. Methods: A prospective study of 66 patients who received Sorafenib for advanced HCC was carried out for a duration of 1 year with a mean follow up of 3 months. Effectiveness was analyzed based on Alpha- Fetoprotein (AFP) levels from laboratory findings. The adverse events (AEs) were graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. In addition, the quality of life (QoL) was analyzed using: EORTC-QLQ-HCC18 (European organization for research and treatment of cancer- Quality of life group questionnaire) and FACT-Hep (Functional assessment of cancer therapy). Result: The patients__ampersandsignrsquo; median age was 63 years (range 61-70) with the male to female ratio of 16:1. The major adverse effects observed were fatigue (31.81%), hand foot syndrome (24.24%) and diarrhea (24.24%). A statistically significant decline in Alpha Fetoprotein (AFP) level was observed with Sorafenib treatment (p=__ampersandsignlt;0.001). The QoL was observed to be better and did not worsen during the therapy. Conclusion: Sorafenib is ideal for patients with advanced HCC, irrespective of baseline status with a good clinical profile.